LQDA · Liquidia Corporation
$42.65
+7.46% last session
End-of-day data · close of 2026-10-23
Market cap
$4B
Enterprise value
$4B
Trailing P/E
30.7
Forward P/E
19.5
Dividend yield
0.0%
Beta
0.61
Avg volume
3M
Employees
0K
Daily Change %
7.46%
5 Days Change
15.55%
10 Days Change
48.04%
30 Days Change
-41.19%
60 Days Change
-43.52%
Month to Day Change
41.80%
Year to Day Change
15.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LQDA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$33.00
-22.6% vs priceBank of America
Neutral$92.00
+115.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Maintains | Buy | $58.00 → $65.00 |
| 2026-10-14 | LifeSci Capital | Upgrade | Market Perform → Outperform | $0.00 → $59.00 |
| 2026-10-14 | Wells Fargo | Maintains | Equal-Weight | $30.00 → $33.00 |
| 2026-10-14 | Needham | Maintains | Buy | $72.00 → $58.00 |
| 2026-10-14 | BTIG | Upgrade | Neutral → Buy | $0.00 → $70.00 |
| 2026-10-02 | Wells Fargo | Downgrade | Overweight → Equal-Weight | $108 → $30.00 |
| 2026-10-02 | HC Wainwright & Co. | Maintains | Buy | $130 → $58.00 |
| 2026-10-01 | Raymond James | Downgrade | Strong Buy → Outperform | $106 → $53.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 23.8% below the 50-day MA ($55.95).
- bearish: Price vs 200-day MA: Trading 21.1% below the 200-day MA ($54.08).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.52) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($22.02) and high ($91.03).
LQDA Price Chart
Loading chart for LQDA…
Fundamentals
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.